29 Sex Differences in Chronic Coronary Syndrome: Data from the ILIAS Physiology Registry to women (15.5% 10.3% respectively, p < 0.01). Women were more likely to have CMD compared to men (28.5% vs. 22.6% respectively, p < 0.01). Lastly, there was a similar occurrence of normal invasive physiologic measurements in both women and men (32.9% vs. 30.0% respectively, p = 0.23). Patient characteristics stratified according to CCS endotype are shown in Table 2. Table 2. Baseline characteristics per CCS-endotype oCAD Revasc CMD Normal Total number of patients n = 259 (14.1) n = 567 (30.9) n = 443 (24.2) n = 564 (30.8) Total number of vessels n = 308 (13.2) n = 651 (27.9) n = 586 (25.1) n = 787 (33.8) Demographics Men, % 210 (81.1) 433 (76.4) 307 (69.3) 407 (72.2) Age, yrs 62.6 ±10.5 64.2 ±10.3 65.4 ±10.0 63.0 ±10.2 Ejection fraction, % 61.3 ±9.4 60.5 ±9.5 60.5 ±10.1 61.4 ±8.6 Coronary risk factors Hypertension, % 155 (59.9) 345 (61.2) 269 (60.9) 329 (58.3) Hyperlipidemia, % 193 (74.2) 392 (69.4) 289 (65.1) 361 (64.0) Positive family history, % 95 (38.3) 165 (31.2) 137 (33.4) 166 (30.3) Current smoking, % 60 (23.5) 140 (25.0) 79 (18.0) 121 (21.8) Diabetes mellitus, % 77 (29.6) 180 (31.8) 115 (25.9) 144 (25.6) Prior myocardial infarction, % 54 (20.8) 146 (25.8) 85 (19.1) 93 (16.5) Prior coronary intervention, % 70 (29.3) 149 (29.6) 109 (28.1) 145 (26.7) Medication at hospital admission Beta-blocker, % 122 (50.8) 294 (58.7) 185 (47.7) 240 (44.2) Nitrates, % 106 (45.3) 182 (38.1) 140 (36.3) 192 (35.8) Calcium antagonist, % 102 (42.5) 215 (42.7) 164 (42.2) 219 (40.3) ACE-inhibitors, % 113 (47.1) 239 (47.6) 173 (44.5) 223 (41.0) Aspirin, % 208 (87.4) 453 (90.1) 308 (79.2) 436 (80.2) Data presented as n(%) or mean ±standard deviation. Abbreviations: yrs: years; ACE: Angiotensin-Converting Enzyme 2
RkJQdWJsaXNoZXIy MTk4NDMw